Blog
RSS FeedPosted by Michael Wonder on 27 Nov 2017
Revised process for filing CDR submissions and resubmissions
27 November 2017 - The CADTH Common Drug Review is aligning the process for secure file sharing with the pan-Canadian ...
Posted by Michael Wonder on 16 Nov 2017
Industry fees are applicable to all CDR resubmissions
13 November 2017 - All resubmissions that are filed by manufacturers on or after 2 January 2018 will be subject to ...
Posted by Michael Wonder on 15 Nov 2017
Revised procedure for the CADTH Common Drug Review resubmissions
13 November 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements ...
Posted by Michael Wonder on 11 Oct 2017
CDR Update — Issue 129
11 October 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission ...
Posted by Michael Wonder on 04 Oct 2017
New members appointed to CADTH expert committees
2 October 2017 - Dr. Brian O’Rourke, CADTH President and Chief Executive Officer, is pleased to announce the appointment of four ...
Posted by Michael Wonder on 02 Oct 2017
Revised procedure for advance notification of pending CDR submissions and resubmissions
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
Posted by Michael Wonder on 15 Aug 2017
Posting of key milestones for CDR projects
14 August 2017 - Key milestones for CDR submissions, resubmissions, and requests for advice will now be posted within the ...
Posted by Michael Wonder on 03 Aug 2017
Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases
2 August 2017 - Positive recommendation moves Erelzi closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 01 Aug 2017
Sharing patient input submissions for the CDR program
1 August 2017 - Since February 2014, CADTH has shared patient input submissions on our website, when permission has been ...
Posted by Michael Wonder on 01 Aug 2017
Proposed revisions to CADTH’s biosimilar review process
1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...
Posted by Michael Wonder on 13 Jul 2017
Proposed revision to the procedure for the CADTH Common Drug Review and the CADTH Therapeutic Review Framework
13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common ...
Posted by Michael Wonder on 13 Jun 2017
Integrating companion diagnostics into CDR and pCODR reviews
13 June 2017 - In November 2016, CADTH invited stakeholder comments and feedback on a proposed process for the assessment ...
Posted by Michael Wonder on 11 Jun 2017
Subsequent entry products for non-biological complex drugs
9 June 2017 - In order to reflect the current environment for subsequent entry non-biological complex drugs, CADTH, in consultation ...
Posted by Michael Wonder on 29 May 2017
CADTH publishes final recommendations for two Servier medicines
25 May 2017 - CADTH has published outcomes for edoxaban tosylate (Lixiana) and ivabradine hydrochloride (Lancora). ...
Posted by Michael Wonder on 25 May 2017
CADTH recommends reimbursement of Gilead's Odefsey
25 May 2017 - The CADTH Canadian Drug Expert Committee has recommended that emtricitabine/rilpivirine/tenofovir alafenamide be reimbursed as a complete ...